IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Heroin Dependence Opioid-Related Disorders | Drug: Hydromorphone | Phase 1 |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Biobehavioral Study of Opioid Drug Seeking Behavior: Study 2 |
| Estimated Enrollment: | 16 |
| Study Start Date: | August 2005 |
Drug dependence is often characterized by severe drug seeking behavior. Learning to understand, predict, and control this maladaptive choice behavior may lead to improved prevention and treatment strategies. HYD is a drug that is currently used as a cough suppressant and to relieve pain. The purpose of this study is to determine the extent to which opioid drug seeking behavior by heroin dependent individuals can be reduced by environmental factors, including supplemental opioid drug availability, drug price, and alternative non-drug reinforcers. Specifically, this study will determine whether knowledge of post-session HYD availability influences drug seeking behavior in heroin dependent individuals, who are maintained on buprenorphine during their participation.
Participants in this observational study will take part in multiple trials in which they have the opportunity to choose either HYD or money. On the first two experimental days, prior to choice sessions, participants will receive a sample of the drug doses that can be chosen. During test sessions, participants will have 12 opportunities to choose either drug or money. Participants will use a computer to earn choices. Respiration rate, oxygen saturation, heart rate, and blood pressure will be monitored throughout choice trials. Supplemental HYD will be made available following some choice sessions. Self-report questionnaires will be completed at different times during the study. Participants will be maintained on buprenorphine throughout the study, with a minimum 2-week lead before the experiment, and a fixed 3-week detoxification after study completion.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Opioid dependent, as determined by the structured clinical interview for DSM-IV (SCID) and Addiction Severity Index (ASI)
- Positive urine test for opiates
- Willing to use an adequate form of contraception for the duration of the study
- Reads and writes English
Exclusion Criteria:
- Psychiatric illness, as determined by the DSM-IV criteria
- History of or current neurological disease, including structural abnormalities, seizures, infection, peripheral neuropathy, and head traumas
- History of cardiovascular disease, myocardial infarction, chest pain, or edema
- Systolic blood pressure greater than 160 mm Hg or less than 95 mm Hg; PR diastolic blood pressure greater than 95 mm Hg
- Pulmonary disease, including obstructive pulmonary disease, cor pulmonale, tuberculosis, and asthma
- Systemic disease (e.g., endocrinopathies, liver or kidney failure, myxedema, hypothyroidism, Addison's disease, autoimmune disease)
- Current alcohol or sedative drug dependence
- Pregnant or breastfeeding
- Currently receiving treatment for opioid dependence
- Known phobia of injections
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00218361
| United States, Michigan | |
| Wayne State University | |
| Detroit, Michigan, United States, 48207 | |
| Principal Investigator: | Mark Greenwald, PhD | Wayne State University |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Mark Greenwald, PhD, Principal Investigator, Wayne State University |
| ClinicalTrials.gov Identifier: | NCT00218361 History of Changes |
| Other Study ID Numbers: |
NIDA-15462-2 R01DA015462 ( US NIH Grant/Contract Award Number ) R01-15462-2 DPMC |
| Study First Received: | September 16, 2005 |
| Last Updated: | June 1, 2012 |
Keywords provided by Mark Greenwald, PhD, Wayne State University:
|
Behavioral economics Drug self administration Opioid |
Additional relevant MeSH terms:
|
Heroin Dependence Opioid-Related Disorders Drug-Seeking Behavior Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Analgesics, Opioid |
Hydromorphone Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on June 22, 2017